Biomerica price to free cash flow BMRA

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 16.0×; Aug 2022
Peer median: 10.4×

Biomerica's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2022, at 16.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	16.0×	13.1×	21.2×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	32.7×	11.7×	41.4×
2013	11.8×	4.8×	75.9×
2012	32.7×	31.0×	32.7×

Against its peers

Companies in Healthcare nearest Biomerica's size, closest first, today.

Company	Price to free cash flow
BMRABiomerica	n/m
NEPHNephros	n/m
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	9.7×
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
Peer median	10.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Biomerica

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.